Psychemedics CORP: directors' dealings · United States · SEC (Form 4)

About Psychemedics CORP

Psychemedics Corp. (ticker: PMDI) is a U.S.-based company focused on hair-based drug testing and related laboratory services. It is no longer listed on Nasdaq; following a voluntary delisting in late 2024, the common stock began trading on the OTC Market on December 13, 2024 under the PMDI symbol. The company’s corporate headquarters are now in Dallas, Texas, in the United States, after a relocation from Acton, Massachusetts. Psychemedics traces its scientific roots to the late 1970s and has marketed its hair-testing technology commercially since 1986, positioning itself as a pioneer in the category. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai)) From a business-model perspective, Psychemedics derives revenue primarily from drug-testing services rather than from physical consumer products. Its proprietary hair-testing platform is used by employers, government entities, law-enforcement agencies, schools, and other institutions for pre-employment screening, random testing, and policy enforcement. The company’s competitive positioning is built on scientific specialization, patent-protected methods, and a long operating history in a niche segment where client trust and analytical credibility are critical. Psychemedics consistently presents itself as the world leader in hair testing for drugs of abuse, emphasizing the method’s longer detection window versus traditional urine testing and its utility in identifying repeated or historical use patterns. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai)) Its offering includes hair-analysis tests covering multiple drug classes, plus a home-collection service intended for parents concerned about potential substance use by children. The company also highlights FDA 510(k)-cleared assays and a broad portfolio designed for workplace, public-sector, and family-use cases. Geographically, Psychemedics serves clients in the United States and internationally, including Fortune 500 companies and a range of public institutions. The market opportunity is niche but recurring, with demand driven by compliance, workplace safety, and the need for more persistent detection capabilities. ([psychemedics.com](https://www.psychemedics.com/about/?utm_source=openai)) Recent developments have been dominated by capital-markets restructuring and operating updates. In December 2024, the company implemented a reverse stock split followed immediately by a forward split, and it also moved from Nasdaq to OTC trading. Its third-quarter 2024 results, released in November 2024, showed lower revenue year over year for both the quarter and the first nine months, although net losses improved versus the prior-year period. For investors, the key questions are whether Psychemedics can defend its niche leadership, maintain client relationships, and convert its scientific edge into more stable financial performance after the listing change. ([investors.psychemedics.com](https://investors.psychemedics.com/news-releases/news-release-details/psychemedics-corporation-reports-third-quarter-2024-financial?utm_source=openai))